Phylos Bioscience specializes in the development of F1 hybrid seeds designed to enhance cannabis cultivation. Their innovative approach focuses on producing fully-feminized, true F1 hybrid seeds that offer high THC levels, unique aromas, and improved agronomic traits. This technology empowers growers of all sizes to achieve higher quality yields in a cost-effective manner, addressing the challenges associated with traditional clonal cultivars. The company emphasizes the importance of uniformity in seed-grown plants, demonstrating through their Uniformity Study that their seeds can match the consistency of clonal varieties in key metrics such as harvest height, wet biomass, and total THC content.

Additionally, Phylos is actively engaged in addressing the risks associated with cannabis cultivation, particularly the HLVd (Hop Latent Viroid) risk. Their breeding experts discuss strategies to mitigate these risks by utilizing F1 hybrid seeds, which are designed to be production-ready and resilient. This focus on genetic innovation not only aims to improve the health and quality of cannabis strains but also positions Phylos as a leader in the evolving landscape of cannabis genetics, unlocking the potential of rare cannabinoids and enhancing the overall cultivation experience for growers.

United States

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

Phylos Bioscience

Company Details